News

PolyMedix has declared that it has received a phase-II Small Business Innovation Research (SBIR) grant in the amount of $923,080. The fund will be disbursed over a period

VIA Pharmaceuticals  has met FDA for its lead drug, VIA-2291 (atreleuton). The company has reviewed safety and biologic activity data from the Via-2291 phase 2 CEA and ACS

Emergent has announced that it has met with the FDA to review regulatory strategy for the development of recombinant anthrax (rPA) vaccine. Emergent recently submitted rPA Development Plan

Meridios has received official notification from the Centers for Medicare & Medicaid Services that it has earned the status of CMS PQRI qualified registry, using its healthMATRIX health

Dow, a chemical company has unveiled the newly-formed Dow Coatings Materials. Following the acquisition, Dow Coatings Materials provides a wide range of chemistries and support across many different

Dow has announced that it has launched a new business and innovation hub in the Asia Pacific region, the Shanghai Dow Center. Occupying more than 100,000 square meters,

Eli Lilly has announced that the FDA Psychopharmacologic Drugs Advisory Committee (PDAC) has voted that Zyprexa (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute

Emergent has announced that BioThrax (Anthrax Vaccine Adsorbed) has been granted a shelf life extension from 3 to 4 years by the FDA. Based on the approval, Emergent

California-based Orexigen has announced the licensing of certain intellectual property (IP) from GlaxoSmithKline (GSK), that expands the company’s IP position underlying Contrave, its lead product candidate for the